Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2025 | $179.00 | Equal Weight → Overweight | Wells Fargo |
| 2/5/2025 | $140.00 → $150.00 | Hold → Buy | Jefferies |
| 1/8/2025 | $130.00 → $144.00 | Hold → Buy | TD Cowen |
| 1/7/2025 | $140.00 | In-line → Outperform | Evercore ISI |
| 1/6/2025 | $132.00 → $145.00 | Neutral → Buy | BofA Securities |
| 12/13/2024 | $101.00 → $127.00 | Underweight → Equal Weight | Wells Fargo |
| 12/4/2024 | $139.00 | Outperform | Mizuho |
| 2/26/2024 | $125.00 | Outperform | Leerink Partners |
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv
NEW YORK, June 12, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on June 12th Stocks are down fractionally this morning after the S&P 500 ended a three-day win streak yesterday. The major index is about 2% from its record.Amid the market momentum, Voyager Technologies (NYSE:VOYG) and Ategrity (NYSE: ASIC) popped double digits in their debuts yesterday. Voyager is a $3.1 billion space and defense company. Ategrity is an insurer valued at about $1.2 billio
Key announcements: Raising FY25 non-GAAP diluted EPS guidance to $8.15 to $8.201Establishing preliminary FY26 non-GAAP diluted EPS guidance of $9.10 to $9.30 (13% growth at the mid-points)2Confirming long-term target of 12% to 14% non-GAAP diluted EPS CAGR for FY26 to FY283Raising long-term target for Pharmaceutical and Specialty Solutions profit to 5% to 7% normalized growth3,4Raising long-term target for Other profit to ~10% normalized growth3,4,5Updating GMPD long-term target to $50M+ of profit growth per year after FY26Expecting at least $10B in total adjusted free cash flow over next three yearsRaising baseline share repurchase plans to at least $750M per yearCompany reiterating strateg
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
4 - CARDINAL HEALTH INC (0000721371) (Issuer)
3 - CARDINAL HEALTH INC (0000721371) (Issuer)